Little by little, the truth is coming out. I am not sure how the findings of the study below will be reconciled with the widespread usage of SSRI drugs, but they do, once again, confirm Ray’s warnings about 5-HT. The study is particularly important as it is one of the few that used a 5-HT synthesis inhibitor, instead of a 5-HT antagonist. There is a much larger number of studies with 5-HT antagonists showing therapeutic effects in many different cancers, but the pushback I have always received from doctors is that those 5-HT antagonists have other receptor activity as well, and as such they do not uniquely implicate 5-HT as a oncogenic endogenous substance. Well, the study below finally puts this argument to rest by showing that systemic inhibition of the 5-HT synthesis by blocking the enzymes tryptophan hydroxylase is beneficial in multiple human cancers (two types of pancreatic and one type of colon cancer).
https://doi.org/10.1007/s40268-026-00544-x
“…The results were unambiguous at the cellular level. Telotristat ethyl reduced cell viability in all three lines, with half-maximal inhibitory concentrations of 20.71 micromolar in BON-1, 23.71 micromolar in QGP-1 and 11.43 micromolar in HROC57.”
“…The authors are careful about what these results do and do not establish. Telotristat ethyl showed antitumor activity in their models, consistent with inhibition of serotonin biosynthesis, but the relative contribution of serotonin depletion versus other mechanisms remains to be determined, particularly since earlier work by other groups found that telotristat potently suppresses serotonin secretion with only limited effects on proliferation in certain in vitro models”